Recent observations in Alzheimer's disease suggest that factors, which influence the relationship between pathological features in the brain and clinical symptoms, play a significant role in the disease process. First, more than 25% of non-demented, elderly individuals have brain pathology that is indistinguishable from known Alzheimer's disease individuals. Second, among those with a clinical diagnosis of disease there are clearly "fast progressors" and "slow progressors". We will perform a genome-wide screen for relationship loci (rQTL) that modify the known relationship (correlation) between cerebrospinal fluid A?42 levels and case/control status, thus screening for loci that explain the observation of non-demented individuals with Alzheimer's disease pathology. With slight adjustments to our models we can also screen for loci, which modify the known relationship between cerebrospinal fluid A?42 levels and tau levels, and may explain the variation in the rate of progression of disease. For these analyses we have assembled over 2,000 samples with cerebrospinal fluid biomarker measurements, clinical evaluations, and whole-genome marker data for discovery and nearly 1000 samples with cerebrospinal fluid biomarker measurements and clinical evaluations for replication (genotyping to be completed as part of this proposal). We will then test the replicated variants for association with risk and rate of progression of Alzheimer's disease in approximately 20,000 cases and 30,000 controls (over 1900 of which have longitudinal measurements of disease progression). As demonstrated by our preliminary analyses, this promising approach will leverage the largest sample of its kind to identify genetic variation that is associated with Alzheimer's disease and Alzheimer's disease biomarkers via pleiotropic and interaction effects. This will provide insight into variation in important disease related processes such as protein aggregation and inflammatory and immune response. These findings are likely to be important for other protein aggregation and/or protein misfolding diseases.

Public Health Relevance

The broad, long-term goal of our research is to solve the complex genetic architecture of Alzheimer's Disease, which will lead to better strategies for treatment and prevention of this devastating disease. In this proposal we will test hypotheses that genetic factors influence important clinical observations, such as the observation of Pleiotropic effects of APOE e4 on cerebrospinal fluid A? and tau levels, non-demented individuals with Alzheimer's disease pathology and variation in the rate of progression in clinically diagnosed Alzheimer's disease cases. We will use genome-wide marker data to detect loci that simultaneously affect cerebrospinal fluid amyloid beta and tau levels (pleiotropy), the relationships between Alzheimer's disease biomarkers (cerebrospinal fluid amyloid beta and tau) and Alzheimer's disease (referred to as rQTL), and gene-by-gene interactions. Identified loci are likely to affect both risk and/or progression of AD and will shed light on pathways connecting cerebrospinal fluid amyloid beta, tau, and Alzheimer's Disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
1R01AG042611-01
Application #
8344487
Study Section
Molecular Neurogenetics Study Section (MNG)
Program Officer
Miller, Marilyn
Project Start
2012-09-01
Project End
2017-12-31
Budget Start
2012-09-01
Budget End
2013-12-31
Support Year
1
Fiscal Year
2012
Total Cost
$237,731
Indirect Cost
$73,731
Name
Brigham Young University
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
009094012
City
Provo
State
UT
Country
United States
Zip Code
84602
Cao, Ying; Wei, Peng; Bailey, Matthew et al. (2014) A versatile omnibus test for detecting mean and variance heterogeneity. Genet Epidemiol 38:51-9
Benitez, Bruno A; Jin, Sheng Chih; Guerreiro, Rita et al. (2014) Missense variant in TREML2 protects against Alzheimer's disease. Neurobiol Aging 35:1510.e19-26
Sharp, Aaron R; Ridge, Perry G; Bailey, Matthew H et al. (2014) Population substructure in Cache County, Utah: the Cache County study. BMC Bioinformatics 15 Suppl 7:S8
Ebbert, Mark T W; Wadsworth, Mark E; Boehme, Kevin L et al. (2014) Variant Tool Chest: an improved tool to analyze and manipulate variant call format (VCF) files. BMC Bioinformatics 15 Suppl 7:S12
Ridge, Perry G; Maxwell, Taylor J; Foutz, Spencer J et al. (2014) Mitochondrial genomic variation associated with higher mitochondrial copy number: the Cache County Study on Memory Health and Aging. BMC Bioinformatics 15 Suppl 7:S6
Peterson, David; Munger, Caitlin; Crowley, Jared et al. (2014) Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study. Alzheimers Dement 10:366-71
Ebbert, Mark T W; Ridge, Perry G; Wilson, Andrew R et al. (2014) Population-based analysis of Alzheimer's disease risk alleles implicates genetic interactions. Biol Psychiatry 75:732-7
Kauwe, John S K; Bailey, Matthew H; Ridge, Perry G et al. (2014) Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. PLoS Genet 10:e1004758
Cruchaga, Carlos; Karch, Celeste M; Jin, Sheng Chih et al. (2014) Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature 505:550-4
Gross, Alden L; Sherva, Richard; Mukherjee, Shubhabrata et al. (2014) Calibrating longitudinal cognition in Alzheimer's disease across diverse test batteries and datasets. Neuroepidemiology 43:194-205

Showing the most recent 10 out of 17 publications